Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
OK folks … please don’t shoot the messenger … I do not agree with the suggestions about the need for another trial in an article published today by the Financial Times. However, I would be a pretty poor reporter if I didn’t let you know this article is out there in a major international newspaper! [...]
Filed under: Drugs in development | Tagged: Dendreon, Provenge | 3 Comments »
There are several articles that may be of interest to readers in the April issue of the AUA News, which is now available on line.
Filed under: Diagnosis, Management, Risk | Tagged: biopsy, Diagnosis, kinetics, prognosis, PSA, risk, saturation | 1 Comment »
According to a Reuters story earlier today, the results of the 8,000-patient REDUCE trial of dutasteride (Avodart) in prevention of prostate cancer will be presented on April 27 at the annual meeting of the American Urological Association.
Filed under: Diagnosis, Prevention, Risk | Tagged: dutasteride, Prevention, REDUCE trial | Leave a Comment »
According to a statement by Dendreon on a teleconference early this morning and also in a media release on the company web site, the investigational agent sipleucel-T (Provenge) has met the prespecified end-point for extending survival of patients with hormone-refractory prostate cancer in the Phase III IMPACT trial compared to placebo.
Filed under: Drugs in development | 8 Comments »
Over the years there have been several studies suggesting that regular use of non-steroidal anti-inflammatory agents (NSAIDs) — the most common being aspirin — can decrease prostate inflammation and prostate cancer risk. Since aspirin and other NSAIDs are commonly used to prevent cardiovascular disease, it will be apparent that there is going to be relatively [...]
Filed under: Diagnosis, Risk | Tagged: aspirin, NSAID, Prevention, PSA level, volume | Leave a Comment »
According to a media release from Dendreon earlier this evening, there will be a conference call at 9 am EST/6 am PT tomorrow morning (Tuesday, April 14) at which the company will “review the outcome of the FINAL analysis of its IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE® [...]
Filed under: Drugs in development | Tagged: Provenge, sipuleucel-T | Comments Off
… a paper from the University of Texas Health Sciences Center in San Antonio has provided a detailed analysis of the spectrum of variation of PSA and DRE data among men in an earlier screening program.
Filed under: Diagnosis, Risk | Tagged: changes over time, DRE, PSA, screening | 3 Comments »
It appears that former Israeli prime minister Ehud Olmert has caused a stir by going outside the country for further consultation on treatment for his prostate cancer. He seems to have been on some form of active surveillance protocol since his original diagnosis in 2007.
Filed under: Living with Prostate Cancer, Management | Tagged: Olmert | 1 Comment »
The concurrence of the Passover and Easter holidays this year appears to have limited medical science reports this weekend. There are really only two reports worth mentioning, and even they are of limited interest.
Filed under: Drugs in development, Management, Treatment | Tagged: "high risk", adjuvant therapy, immunotherapy, post-prostatectomy, vaccines | Leave a Comment »
There are two basic types of transrectal ultrasound probe most commonly used to monitor positioning of biopsy needles during the biopsy procedure — the so-called “side fire” and “end fire” types. A recent analysis of data from the Cleveland Clinic suggests that the type of ultrasound probe used may significantly affect the likelihood of diagnosis.
Filed under: Diagnosis, Risk | Tagged: Diagnosis, probe, transrectal ultrasound, type | Leave a Comment »
An article in the current issue of Cancer Research discusses some work that might lead to the type of test we really need to be able to diagnose clinically significant prostate cancer at an early stage and differentiate between this type of prostate cancer and indolent disease.
Filed under: Diagnosis, Risk | Tagged: mRNA, new, SLC45A3-ELK4, test | 1 Comment »
Today’s news reports deal with: A comparative, single institution study of RALP vs RRP Bone mineral density and osteoporosis in men treated with intermittent hormone therapy Transdermal testosterone therapy in men with castration-resistant prostate cancer In a separate report we have discussed the development of a pre-biopsy risk assessment nomogram that incorporates results from PCA3 [...]
Filed under: Management, Treatment | Tagged: BMD, bone mineral density, intermittent hormone therapy, osterporosis, RALP, retropubic radical prostatectomy, robot-assisted laparoscopic prostatectomy, RRP, testosterone therapy | Leave a Comment »
There has been hope in some quarters that the prostate cancer gene 3 or PCA3 test would provide data so helpful that we could dispense with the need for PSA testing at all. However, The “New” Prostate Cancer Infolink has long suspected — for a variety of reasons — that this would not be the [...]
Filed under: Diagnosis, Risk | Tagged: nomogram, PCA3, pre-biopsy, value | 7 Comments »
Although the pros and cons of mass screening for prostate cancer have been the focus of extensive discussion on this site and elsewhere in recent weeks, some readers may be aware that this is just a part of a broader discussion of the appropriateness of mass screening for a variety of chronic diseases. An editorial [...]
Filed under: Diagnosis, Risk | Tagged: risk, screening | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site